These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32677060)

  • 1. The Relationship between the Initial Anti-factor Xa Measurement and the Duration of Direct Oral Anticoagulant Influence in Patients Transitioning to Heparin.
    Plum MD; Hedrick JN; Hockman R; Bazydlo L; Palkimas S
    Pharmacotherapy; 2020 Sep; 40(9):880-888. PubMed ID: 32677060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Direct Oral Anticoagulants on Anti-Factor Xa Measurements Utilized for Monitoring Heparin.
    Macedo KA; Tatarian P; Eugenio KR
    Ann Pharmacother; 2018 Feb; 52(2):154-159. PubMed ID: 28862013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-Calibrated Anti-Factor Xa Assay for the Measurement of Direct Anticoagulants such as Apixaban, Rivaroxaban, and Edoxaban.
    Ahn HS; Chae H; Kim Y; Lee HK; Kim H
    Clin Lab; 2024 Sep; 70(9):. PubMed ID: 39257123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interference of oral anti-Xa anticoagulants during monitoring of unfractionated heparin treatments: practical and future attitudes].
    Melicine S; Maucorps L; Eschwège V; Carré J; Helley D; Gouin-Thibault I; Gendron N; Nédélec-Gac F; Mauge L
    Ann Biol Clin (Paris); 2024 Jun; 82(2):129-138. PubMed ID: 38832688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of specific anti-Xa levels in acute kidney injury to transition patients from oral factor Xa inhibitors to i.v. heparin infusion.
    Zochert S; Oltman KM; Elgersma BM; Hellwig TR; Gulseth MP
    Am J Health Syst Pharm; 2019 Apr; 76(8):505-511. PubMed ID: 31361865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transitioning hospitalized patients from rivaroxaban or apixaban to a continuous unfractionated heparin infusion: A retrospective review.
    Smith AR; Dager WE; Gulseth MP
    Am J Health Syst Pharm; 2020 Aug; 77(Suppl 3):S59-S65. PubMed ID: 32719867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DOAC-Remove to counteract the interference of anti-Xa oral anticoagulants on the monitoring of heparin.
    Melicine S; Habay C; Ghammad W; Carré J; Diehl JL; Smadja DM; Gendron N; Helley D; Mauge L
    Int J Lab Hematol; 2024 Oct; 46(5):953-962. PubMed ID: 38803134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions.
    Faust AC; Kanyer D; Wittkowsky AK
    Am J Health Syst Pharm; 2016 Dec; 73(24):2037-2041. PubMed ID: 27919873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS
    Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Systemwide Approach for Navigating the Dilemma of Oral Factor Xa Inhibitor Interference With Unfractionated Heparin Anti-Factor Xa Concentrations.
    Levito MN; Coons JC; Verrico MM; Szymkowiak A; Legler B; Dueweke EJ; Kane-Gill SL
    Ann Pharmacother; 2021 May; 55(5):618-623. PubMed ID: 32885997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of apixaban on antifactor Xa levels in a patient with acute kidney injury.
    Wendte J; Voss G; VanOverschelde B
    Am J Health Syst Pharm; 2016 Apr; 73(8):563-7. PubMed ID: 27045068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different Coagulation Indicators in Predicting Clinical Outcomes for Patients With Direct Oral Anticoagulants: A Systematic Review and Meta-analysis.
    Liu Z; Zhang H; Xie Q; Mu G; Zhou S; Wang Z; Wang Z; Jiang J; Xiang Q; Cui Y
    Clin Ther; 2020 Oct; 42(10):2066-2081.e9. PubMed ID: 32900534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perils of Antithrombotic Transitions: Effect of Oral Factor Xa Inhibitors on the Heparin Antifactor Xa Assay.
    Ahuja T; Yang I; Huynh Q; Papadopoulos J; Green D
    Ther Drug Monit; 2020 Oct; 42(5):737-743. PubMed ID: 32433187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays.
    Gosselin R; Grant RP; Adcock DM
    Int J Lab Hematol; 2016 Oct; 38(5):505-13. PubMed ID: 27265752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
    Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
    J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.